In the BioHarmony Drug Report Database
Burosumab
Crysvita (burosumab) is an antibody pharmaceutical. Burosumab was first approved as Crysvita on 2018-02-19. It has been approved in Europe to treat familial hypophosphatemia and familial hypophosphatemic rickets. The pharmaceutical is active against fibroblast growth factor 23.
Trade Name
|
Crysvita |
|---|---|
Common Name
|
burosumab |
ChEMBL ID
|
CHEMBL3707326 |
Indication
|
familial hypophosphatemia, familial hypophosphatemic rickets |
Drug Class
|
Monoclonal antibodies: fully human, bone target |
Image (chem structure or protein)
